(MIRM) Mirum Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.745m USD | Total Return: 140.5% in 12m

Rare Disease Treatments, Liver Therapies, Bile Acid Drugs
Total Rating 55
Safety 35
Buy Signal -0.25
Biotechnology
Industry Rotation: -8.0
Market Cap: 5.74B
Avg Turnover: 76.3M USD
ATR: 4.05%
Peers RS (IBD): 61.3
Risk 5d forecast
Volatility45.2%
Rel. Tail Risk-11.5%
Reward TTM
Sharpe Ratio2.07
Alpha101.07
Character TTM
Beta1.077
Beta Downside1.453
Drawdowns 3y
Max DD32.52%
CAGR/Max DD1.75
EPS (Earnings per Share) EPS (Earnings per Share) of MIRM over the last years for every Quarter: "2021-03": -1.69, "2021-06": -1.45, "2021-09": -1.55, "2021-12": -1.66, "2022-03": -1.17, "2022-06": -0.84, "2022-09": -1.02, "2022-12": -0.99, "2023-03": -0.8, "2023-06": -1.94, "2023-09": -0.57, "2023-12": -0.66, "2024-03": -0.54, "2024-06": -0.52, "2024-09": -0.2979, "2024-12": -0.49, "2025-03": -0.3, "2025-06": -0.12, "2025-09": 0.05, "2025-12": -0.12,
EPS CAGR: 24.46%
EPS Trend: 84.0%
Last SUE: -0.31
Qual. Beats: 0
Revenue Revenue of MIRM over the last years for every Quarter: 2021-03: 0, 2021-06: 11, 2021-09: 5, 2021-12: 3.138, 2022-03: 12.892, 2022-06: 17.484, 2022-09: 18.78, 2022-12: 27.906, 2023-03: 31.598, 2023-06: 37.497, 2023-09: 47.725, 2023-12: 69.554, 2024-03: 69.222, 2024-06: 77.875, 2024-09: 90.377, 2024-12: 99.414, 2025-03: 111.585, 2025-06: 127.785, 2025-09: 133.01, 2025-12: 148.932,
Rev. CAGR: 92.03%
Rev. Trend: 96.5%
Last SUE: 0.82
Qual. Beats: 0

Warnings

Interest Coverage Ratio -0.7 is critical

Altman Z'' -1.32 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: MIRM Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc. is a biopharmaceutical company specializing in rare and orphan diseases. This business model focuses on developing treatments for conditions affecting small patient populations, often allowing for expedited regulatory review and extended market exclusivity.

The companys primary approved product is LIVMARLI (maralixibat), an IBAT inhibitor for cholestatic pruritus in Alagille syndrome. Mirum also commercializes Cholbam for bile acid synthesis disorders and Chenodal for gallstones and cerebrotendinous xanthomatosis. The pharmaceutical sector often involves significant research and development investments, with a long and complex drug development pipeline.

Mirums pipeline includes Volixibat for cholestatic liver diseases, Brelovitug for chronic HDV infection, and MRM-3379 for FXS, all in various stages of clinical trials. The company maintains multiple collaboration and licensing agreements with other pharmaceutical entities. For a deeper dive into their financial performance and market position, consider exploring further research on platforms like ValueRay.

Headlines to Watch Out For
  • LIVMARLI sales growth drives primary revenue expansion
  • Regulatory approval for new indications expands market access
  • Clinical trial results for pipeline drugs impact future valuation
  • Competition from new therapies threatens market share
  • Manufacturing costs and supply chain stability affect profitability
Piotroski VR‑10 (Strict) 6.0
Net Income: -23.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 8.10 > 1.0
NWC/Revenue: 65.97% < 20% (prev 79.03%; Δ -13.06% < -1%)
CFO/TA 0.07 > 3% & CFO 55.8m > Net Income -23.4m
Net Debt (22.8m) to EBITDA (14.0m): 1.63 < 3
Current Ratio: 2.67 > 1.5 & < 3
Outstanding Shares: last quarter (50.2m) vs 12m ago 3.85% < -2%
Gross Margin: 80.76% > 18% (prev 0.76%; Δ 8.00k% > 0.5%)
Asset Turnover: 68.89% > 50% (prev 50.23%; Δ 18.66% > 0%)
Interest Coverage Ratio: -0.72 > 6 (EBITDA TTM 14.0m / Interest Expense TTM 14.4m)
Altman Z'' -1.32
A: 0.41 (Total Current Assets 549.7m - Total Current Liabilities 205.8m) / Total Assets 842.8m
B: -0.79 (Retained Earnings -667.5m / Total Assets 842.8m)
C: -0.01 (EBIT TTM -10.3m / Avg Total Assets 756.8m)
D: -1.26 (Book Value of Equity -667.2m / Total Liabilities 528.1m)
Altman-Z'' Score: -1.32 = CCC
Beneish M -2.87
DSRI: 1.02 (Receivables 123.3m/78.3m, Revenue 521.3m/336.9m)
GMI: 0.94 (GM 80.76% / 75.77%)
AQI: 0.84 (AQ_t 0.34 / AQ_t-1 0.40)
SGI: 1.55 (Revenue 521.3m / 336.9m)
TATA: -0.09 (NI -23.4m - CFO 55.8m) / TA 842.8m)
Beneish M-Score: -2.87 (Cap -4..+1) = A
What is the price of MIRM shares? As of April 13, 2026, the stock is trading at USD 95.20 with a total of 722,877 shares traded.
Over the past week, the price has changed by -1.08%, over one month by +6.04%, over three months by +6.37% and over the past year by +140.46%.
Is MIRM a buy, sell or hold? Mirum Pharmaceuticals has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MIRM.
  • StrongBuy: 6
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the MIRM price?
Analysts Target Price 125.4 31.7%
Mirum Pharmaceuticals (MIRM) - Fundamental Data Overview as of 12 April 2026
P/E Forward = 2000.0
P/S = 11.0194
P/B = 18.2545
Revenue TTM = 521.3m USD
EBIT TTM = -10.3m USD
EBITDA TTM = 14.0m USD
Long Term Debt = 309.8m USD (from longTermDebt, last quarter)
Short Term Debt = 2.14m USD (from shortTermDebt, last quarter)
Debt = 319.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 22.8m USD (from netDebt column, last quarter)
Enterprise Value = 5.68b USD (5.74b + Debt 319.5m - CCE 383.3m)
Interest Coverage Ratio = -0.72 (Ebit TTM -10.3m / Interest Expense TTM 14.4m)
EV/FCF = 103.5x (Enterprise Value 5.68b / FCF TTM 54.9m)
FCF Yield = 0.97% (FCF TTM 54.9m / Enterprise Value 5.68b)
FCF Margin = 10.53% (FCF TTM 54.9m / Revenue TTM 521.3m)
Net Margin = -4.48% (Net Income TTM -23.4m / Revenue TTM 521.3m)
Gross Margin = 80.76% ((Revenue TTM 521.3m - Cost of Revenue TTM 100.3m) / Revenue TTM)
Gross Margin QoQ = 80.97% (prev 80.80%)
Tobins Q-Ratio = 6.74 (Enterprise Value 5.68b / Total Assets 842.8m)
Interest Expense / Debt = 1.13% (Interest Expense 3.60m / Debt 319.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -8.13m (EBIT -10.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.67 (Total Current Assets 549.7m / Total Current Liabilities 205.8m)
Debt / Equity = 1.02 (Debt 319.5m / totalStockholderEquity, last quarter 314.7m)
Debt / EBITDA = 1.63 (Net Debt 22.8m / EBITDA 14.0m)
Debt / FCF = 0.41 (Net Debt 22.8m / FCF TTM 54.9m)
Total Stockholder Equity = 273.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.09% (Net Income -23.4m / Total Assets 842.8m)
RoE = -8.53% (Net Income TTM -23.4m / Total Stockholder Equity 273.8m)
RoCE = -1.76% (EBIT -10.3m / Capital Employed (Equity 273.8m + L.T.Debt 309.8m))
 RoIC = -1.39% (negative operating profit) (NOPAT -8.13m / Invested Capital 582.9m)
 WACC = 9.30% (E(5.74b)/V(6.06b) * Re(9.77%) + D(319.5m)/V(6.06b) * Rd(1.13%) * (1-Tc(0.21)))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.43%
[DCF] Terminal Value 64.98% ; FCFF base≈54.9m ; Y1≈36.0m ; Y5≈16.5m
[DCF] Fair Price = 4.02 (EV 265.6m - Net Debt 22.8m = Equity 242.9m / Shares 60.3m; r=9.30% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 84.01 | EPS CAGR: 24.46% | SUE: -0.31 | # QB: 0
Revenue Correlation: 96.50 | Revenue CAGR: 92.03% | SUE: 0.82 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.46 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=6
EPS current Year (2026-12-31): EPS=-1.82 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-5 | Growth EPS=-287.2% | Growth Revenue=+23.7%
EPS next Year (2027-12-31): EPS=-0.11 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+94.0% | Growth Revenue=+22.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Current Year)
External Resources
Dataroma Stockcircle